BRAFCON brings together the complementary skills, resources and state-of-the-art technological platforms for mass spectrometry-based proteomics (University of Rijeka Department of Biotechnology) and sphingolipidomics (University of Graz Institute of Molecular Biosciences, Austria) supported by advanced bioinformatics tools (Ingenet. Ltd, UK) to study chemoresistance in BRAFV600-mutant colon cancer and covering the path from target discovery and validation, design of novel combinatorial therapies to their preclinical evaluation.

The project is strongly supported by the internationally recognised scientific expertise of the multidisciplinary team in the field of cancer biology, cell signalling, experimental oncology, mass spectrometry, protein isolation and separation from complex biological samples, proteomics, glycoproteomics and glycomics, cancer secretome analysis, sphingolipidomics, bioinformatics, pathway and network analysis and modelling and preclinical testing of novel anticancer agents.